Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Availability of mechanical circulatory support (MCS) and hospital survival in ST-segment elevation myocardial infarction related cardiogenic shock (STEMI-CS).

European heart journal. Acute cardiovascular care·2026
Same author

Adenotonsillectomy is associated with increased risk and disease activity in pediatric-onset multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Stem-Cell-Derived Biologic Ventricular Assist Tissue in Heart Failure.

The New England journal of medicine·2026
Same author

Effect of anti-fibrotic therapy on regression of myocardial fibrosis after TAVI: design and rationale of the Reduce-MFA DZHK25 trial.

ESC heart failure·2026
Same author

The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial.

Nature medicine·2026
Same author

Longitudinal short-term assessments of single- and multi-protein disease activity biomarkers to determine reliability and the minimum detectable change in people with clinically stable RRMS.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

Long-term use of rozanolixizumab in generalised myasthenia gravis: final pooled analysis of the phase III MycarinG study and two open-label extensions.

Therapeutic advances in neurological disorders·2026
Same journal

Clinical, imaging, and immunotherapeutic features in MOGAD: a retrospective real-world cohort in Northern China.

Therapeutic advances in neurological disorders·2026
Same journal

Narcolepsy with co-occurring epilepsy: diagnostic pitfalls and management strategy.

Therapeutic advances in neurological disorders·2026
Same journal

Paradoxical myocardial infarction risk with dual antiplatelet therapy in East Asian ischaemic stroke: a nationwide real-world cohort study and pharmacogenomic risk prediction model.

Therapeutic advances in neurological disorders·2026
Same journal

Residual early neurological deterioration following dual antiplatelet in stroke: post hoc analysis of the ATAMIS trial.

Therapeutic advances in neurological disorders·2026
Same journal

Brain age gap in multiple sclerosis: associated with disability but independent of serum biomarkers.

Therapeutic advances in neurological disorders·2026
See all related articles

Related Experiment Video

Updated: Sep 24, 2025

Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy
07:20

Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy

Published on: August 9, 2024

1.4K

Improving pediatric multiple sclerosis interventional phase III study design: a meta-analysis.

Jennifer S Graves1, Marius Thomas2, Jun Li2

  • 1Department of Neurosciences, University of California, San Diego, Box 0662 ACTRI, 9452 Medical Center Drive, Suite 4W-222, San Diego, CA 92037, USA.

Therapeutic Advances in Neurological Disorders
|May 6, 2022
PubMed
Summary
This summary is machine-generated.

This study found higher relapse rates in pediatric multiple sclerosis (MS) patients treated with interferon beta (IFN β) compared to fingolimod or natalizumab. These findings support using Bayesian and non-inferiority designs for more efficient clinical trials in pediatric MS.

Keywords:
annualized relapse rateclinical trial designfingolimodinterferonnatalizumabpediatric-onset multiple sclerosissystematic review

More Related Videos

Remotely Supervised Transcranial Direct Current Stimulation: An Update on Safety and Tolerability
08:22

Remotely Supervised Transcranial Direct Current Stimulation: An Update on Safety and Tolerability

Published on: October 7, 2017

8.2K
The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

58.2K

Related Experiment Videos

Last Updated: Sep 24, 2025

Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy
07:20

Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy

Published on: August 9, 2024

1.4K
Remotely Supervised Transcranial Direct Current Stimulation: An Update on Safety and Tolerability
08:22

Remotely Supervised Transcranial Direct Current Stimulation: An Update on Safety and Tolerability

Published on: October 7, 2017

8.2K
The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

58.2K

Area of Science:

  • Neurology
  • Clinical Trials
  • Pharmacology

Background:

  • Pediatric-onset multiple sclerosis (MS) requires innovative clinical trial designs.
  • Interferon beta (IFN β), fingolimod, and natalizumab are key treatments for pediatric MS.
  • Limited data exists on comparative relapse rates in this population.

Purpose of the Study:

  • To conduct a systematic literature review and meta-analysis of relapse rates for IFN β, fingolimod, and natalizumab in pediatric MS.
  • To evaluate the potential benefits of Bayesian and non-inferiority trial designs in this population.
  • To inform regulatory approaches for pediatric MS drug development.

Main Methods:

  • Systematic literature search of MEDLINE and EMBASE up to June 2020.
  • Meta-analysis using a Bayesian random effects model to estimate annualized relapse rates (ARR).
  • Data extraction and quality assessment by two independent researchers.

Main Results:

  • 19 articles, including 2 RCTs, were analyzed.
  • Meta-analysis showed significantly higher ARR with IFN β (0.69) versus fingolimod (0.11) and natalizumab (0.17).
  • Identified non-inferiority margins and demonstrated sample size reduction potential with Bayesian designs.

Conclusions:

  • Relapse rates are substantially higher with IFN β compared to fingolimod or natalizumab in pediatric MS.
  • Bayesian and non-inferiority designs can optimize clinical trials by using historical data.
  • These innovative designs can expedite the delivery of effective treatments to pediatric MS patients.